Medical Excellence Capital

Pleno is a biotechnology company based in San Diego, California, founded in 2017. The company focuses on accelerating disease diagnosis and treatment through its innovative Hypercoding technology, which utilizes signal processing techniques from the telecommunications industry. Pleno has developed a multi-omic instrument for biological target detection that significantly enhances clinical testing and biomedical research. This platform is capable of monitoring minimal residual disease and facilitating early multi-cancer screenings. It also detects a wide array of analytical targets, including DNA, RNA, and protein biomarkers, with exceptional speed and precision. Additionally, Pleno employs advanced microfluidics to automate sample preparation and analysis, thereby providing healthcare providers with diverse health monitoring technologies.

GC Therapeutics specializes in synthetic biology to efficiently program patient-derived stem cells into various cell types. The company has developed a proprietary platform that integrates synthetic biology and artificial intelligence, enabling streamlined manufacturing and improved quality of cell therapies. Their approach allows for the rapid differentiation of pluripotent stem cells, creating unique SuperCells™ customized for specific medical conditions. The foundational technology was developed in Professor George Church's lab at Harvard Medical School, and the team at GC Therapeutics comprises dedicated biologists and tissue engineers focused on translating this innovative method into practical therapies for patients.

Truvian Sciences Inc, based in San Diego, California, specializes in developing automated diagnostic equipment that transforms the blood testing industry. Founded in 2015, the company offers a benchtop system designed to deliver lab-accurate results for a range of health tests. Its comprehensive wellness panel includes commonly ordered routine blood tests such as complete blood count, metabolic panel, and lipid panel, all processed from a single sample. Additionally, Truvian Sciences provides a software platform that enables healthcare practitioners to efficiently share test data with patients.

ProJenX is a clinical-stage biopharmaceutical company based in Nissequogue, New York, focused on developing innovative small molecule therapeutics for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. Founded in 2021, the company specializes in therapies that target motor neuron degenerative pathways. Its lead product is an oral small molecule designed to penetrate the brain and inhibit MAP4 kinases, which has demonstrated efficacy in laboratory models of ALS. This therapeutic approach aims to mitigate endoplasmic reticulum stress-mediated motor neuron loss, offering potential new options for patients suffering from these debilitating conditions.

Avilar Therapeutics is a biopharmaceutical company dedicated to the discovery and development of extracellular protein degraders, which represent an innovative approach to targeted protein degradation. The company has created an integrated discovery platform that extends the concept of protein degradation beyond intracellular proteins. Avilar’s novel degraders are designed to bind to disease-causing proteins in circulation and shuttle them to the hepatocyte endolysosome for degradation. This mechanism aims to facilitate the treatment of serious diseases by removing unwanted proteins from the body, thereby offering potential therapeutic benefits in various medical conditions.

SonoThera is a biotechnology company focused on developing non-viral genetic therapies using ultrasound technology. The company aims to create genetic medicines that address the root causes of human diseases, particularly for conditions that currently have limited or no effective treatments. By leveraging ultrasound-guided nonviral gene therapy, SonoThera seeks to enhance treatment options and improve health outcomes for millions of patients.

Pleno is a biotechnology company based in San Diego, California, founded in 2017. The company focuses on accelerating disease diagnosis and treatment through its innovative Hypercoding technology, which utilizes signal processing techniques from the telecommunications industry. Pleno has developed a multi-omic instrument for biological target detection that significantly enhances clinical testing and biomedical research. This platform is capable of monitoring minimal residual disease and facilitating early multi-cancer screenings. It also detects a wide array of analytical targets, including DNA, RNA, and protein biomarkers, with exceptional speed and precision. Additionally, Pleno employs advanced microfluidics to automate sample preparation and analysis, thereby providing healthcare providers with diverse health monitoring technologies.

Aspen Neuroscience, Inc. is a biotechnology company focused on developing induced pluripotent stem cells (iPSCs) to create patient-specific therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018 and based in San Diego, California, the company is advancing its pipeline of products, which includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited autologous neuron replacement therapy targeting familial forms of the disease. Aspen Neuroscience employs innovative genomic approaches in conjunction with stem cell biology to address diseases with significant unmet medical needs, aiming to provide restorative cell therapies that can modify the progression of Parkinson's disease and potentially extend to other affected organs.

ProJenX is a clinical-stage biopharmaceutical company based in Nissequogue, New York, focused on developing innovative small molecule therapeutics for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. Founded in 2021, the company specializes in therapies that target motor neuron degenerative pathways. Its lead product is an oral small molecule designed to penetrate the brain and inhibit MAP4 kinases, which has demonstrated efficacy in laboratory models of ALS. This therapeutic approach aims to mitigate endoplasmic reticulum stress-mediated motor neuron loss, offering potential new options for patients suffering from these debilitating conditions.

Immunitas Therapeutics, Inc. is focused on developing targeted therapies for cancer patients through innovative single-cell analyses. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes a single-cell sequencing platform to explore the biology of immune cells within human tumors. This approach allows Immunitas to identify novel drug targets rooted in human biology and create key biomarkers that assist in selecting patients who may benefit from their therapies. By translating laboratory findings into clinical applications, Immunitas aims to address longstanding challenges in oncology and improve treatment options for complex cancers. The company is advancing multiple programs toward early human studies, leveraging expertise in antibody discovery and engineering to develop effective treatments.